Published in Headache on September 09, 2009
Schizophrenia susceptibility alleles are enriched for alleles that affect gene expression in adult human brain. Mol Psychiatry (2011) 1.84
A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma (2009) 1.39
Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients. Braz J Med Biol Res (2014) 1.11
Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. J Alzheimers Dis (2011) 0.91
Elevated S100B and neuron specific enolase levels in patients with migraine-without aura: evidence for neurodegeneration? Cell Mol Neurobiol (2011) 0.80
The Role of Adenosine Signaling in Headache: A Review. Brain Sci (2017) 0.75
Higher serum levels of s100b and lower serum levels of NSE in migraineurs. Headache (2009) 0.75
Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study. J Headache Pain (2017) 0.75
Is serum S100B protein an useful biomarker in migraine? Neurol Sci (2014) 0.75
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci (2004) 2.84
The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Mov Disord (2007) 2.64
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord (2003) 2.03
Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr Res (2002) 2.01
The facial expression of pain in patients with dementia. Pain (2007) 2.01
Hyperalgesia and functional sensory loss in restless legs syndrome. Pain (2013) 2.00
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2008) 1.83
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.78
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol (2011) 1.60
NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol (2008) 1.59
Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease. Exp Neurol (2005) 1.58
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord (2005) 1.54
Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes. Mov Disord (2012) 1.50
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
Memory for public events in patients with unilateral temporal lobe epilepsy. Epilepsy Behav (2010) 1.41
Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain (2002) 1.37
Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A (2009) 1.35
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord (2008) 1.33
Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci (2003) 1.30
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem (2005) 1.27
Cytokines and epilepsy. Seizure (2011) 1.26
Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat Neurosci (2011) 1.24
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol (2007) 1.20
Timecourse of health-related quality of life as determined 3, 6 and 12 months after stroke. Relationship to neurological deficit, disability and depression. J Neurol (2002) 1.20
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18
Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci (2007) 1.18
Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord (2010) 1.16
Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem (2003) 1.15
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord (2011) 1.15
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord (2011) 1.14
Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics (2005) 1.13
Rational therapeutic approaches to progressive supranuclear palsy. Brain (2010) 1.11
Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord (2005) 1.09
Lack of differences of motorcortical excitability in the morning as compared to the evening in juvenile myoclonic epilepsy--a study using transcranial magnetic stimulation. Epilepsy Res (2007) 1.07
Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practice. J Neurol (2009) 1.06
Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci (2006) 1.04
Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol (2009) 1.04
Treatment of paroxysmal dyskinesias. Expert Opin Pharmacother (2010) 1.04
Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology (2012) 1.04
Evaluation of costs and outcome in cardioembolic stroke or TIA. J Neurol (2009) 1.04
Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med (2012) 1.02
Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord (2003) 1.01
Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol (2012) 1.00
Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord (2004) 1.00
Influence of dementia on multiple components of pain. Eur J Pain (2008) 1.00
On the relationship between self-report and facial expression of pain. J Pain (2004) 1.00
Health-related quality of life in patients with Gilles de la Tourette's syndrome. Mov Disord (2010) 0.98
Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett (2008) 0.98
Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Exp Neurol (2009) 0.98
Intravenous initiation and maintenance of ketogenic diet: proof of concept in super-refractory status epilepticus. Seizure (2013) 0.98
Costs of Parkinson's disease in eastern Europe: a Czech cohort study. Parkinsonism Relat Disord (2009) 0.97
Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort study. Parkinsonism Relat Disord (2011) 0.96
Prospective evaluation of a post-stroke epilepsy risk scale. J Neurol (2010) 0.96
Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model. PLoS One (2013) 0.96
Language lateralization in children using functional transcranial Doppler sonography. Dev Med Child Neurol (2009) 0.95
Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Res (2009) 0.95
Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem (2011) 0.94
Awareness and knowledge of the clinical practice guideline on Parkinson's disease among German neurologists. Eur Neurol (2009) 0.94
Central sensitization and altered central pain processing in chronic low back pain: fact or myth? Clin J Pain (2013) 0.93
Validation of the "L-DOPA test" for diagnosis of restless legs syndrome. Mov Disord (2006) 0.93
Diffusion tensor imaging in episodic cluster headache. Headache (2011) 0.93
Evaluation of sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep under dopaminergic medication: a pilot study. Mov Disord (2002) 0.93
Gene expression profiles derived from single cells in human postmortem brain. Brain Res Brain Res Protoc (2004) 0.91
Excitability of the motor cortex during ovulatory and anovulatory cycles: a transcranial magnetic stimulation study. Clin Endocrinol (Oxf) (2007) 0.91
Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease. Mov Disord (2013) 0.91
Language lateralization in patients with temporal lobe epilepsy: a comparison of functional transcranial Doppler sonography and the Wada test. Neuroimage (2003) 0.91
The socioeconomic impact of narcolepsy. Sleep (2004) 0.91
Costs of illness in a Russian cohort of patients with Parkinson's disease. Pharmacoeconomics (2009) 0.91
Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults. J Neurol (2012) 0.90
Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord (2003) 0.90
In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS. Mov Disord (2010) 0.90
Adult neurogenesis and Parkinson's disease. CNS Neurol Disord Drug Targets (2007) 0.90
Autosomal dominant congenital nystagmus is not linked to 6p12, 7p11, and 15q11 in a German family. Am J Ophthalmol (2004) 0.90
Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease. J Neuroimmunol (2011) 0.89
Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. J Neuropathol Exp Neurol (2011) 0.89
Impact of age on the facial expression of pain. J Psychosom Res (2008) 0.89
Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Mov Disord (2008) 0.88
Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain Behav Immun (2010) 0.88
The effects of oral contraceptives on detection and pain thresholds as well as headache intensity during menstrual cycle in migraine. Headache (2010) 0.88
Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol (2010) 0.88